Skip to content

Prospective comparison of histologic outcomes between 22G and 25G acquire FNA needle for pancreatic/peripancreatic mass

Prospective comparison of histologic outcomes between 22G and 25G acquire FNA needle for pancreatic/peripancreatic mass

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0003834
Enrollment
140
Registered
2019-04-23
Start date
2018-11-12
Completion date
Unknown
Last updated
2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

a 10-cm3 suction syringe (supplied with the needle by the manufacturer) will be applied to the needle hub. Three passes will be made with each technique, consisting of 10 uniform to-and-fro movements

Sponsors

Asan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients older than 18 years and younger than 80 years 2. Patients with solid pancreatic/peripancreatic mass which is needed pathologic confirmation

Exclusion criteria

Exclusion criteria: 1. cystic pancreatic lesions without the evidence of solid component suspected with malignant transformation 2. cardiopulmonary instability 3. severe coagulopathy (international normalized ratio > 1.5 or platelet count < 50,000 cells/cubic millimeter [cmm3]) 4. inability to suspend antithrombotic therapy 5. pregnancy 6. Patients with underlying co-morbidities preclude sedation 7. GI obstruction or previous stomach surgery that preclude EUS examination 8. refusal to provide informed consent or participate in the study.

Design outcomes

Primary

MeasureTime frame
the procurement rates of histologic cores that the cyto-pathologist considered to be of optimal quality for histological evaluation

Secondary

MeasureTime frame
diagnostic performance: diagnostic accuracy, sensitivity, specificity, positive predictive value, negative predictive value

Countries

Korea, Republic of

Contacts

Public ContactDongwook Oh

Asan Medical Center

wooki219@naver.com+82-2-3010-3189

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026